Quarterly ResultMay 11, 2026, 04:16 PM
ArriVent Q1 Net Loss Narrows to $43.3M; ARR-002 IND Cleared
AI Summary
ArriVent BioPharma reported a reduced net loss of $43.3 million for the first quarter of 2026, compared to $64.4 million in the prior year, with net loss per share improving to $(0.96). Research and development expenses decreased to $37.6 million, while general and administrative expenses increased to $8.5 million. The company's cash and cash equivalents rose to $62.1 million, with total cash and marketable securities at $326.4 million. Additionally, ArriVent received US IND clearance for ARR-002, expecting to initiate a Phase 1 trial in the second half of 2026, and incurred a $6.0 million developmental milestone payment to Lepu Biopharma.
Key Highlights
- Net loss for Q1 2026 was $43.3 million, a decrease from $64.4 million in Q1 2025.
- Net loss per share improved to $(0.96) in Q1 2026 from $(1.90) in Q1 2025.
- Research and development expenses decreased to $37.6 million from $61.3 million year-over-year.
- General and administrative expenses increased to $8.5 million from $5.5 million year-over-year.
- Cash and cash equivalents rose to $62.1 million at March 31, 2026, from $45.5 million.
- Total cash and marketable securities stood at $326.4 million as of March 31, 2026.
- US IND clearance received for ARR-002, with Phase 1 trial initiation expected in H2 2026.
- Incurred a $6.0 million developmental milestone payment to Lepu Biopharma in Q1 2026.
Price Impact
More from AVBP